BRPI0612334A2 - uso de uma abordagem baseada em galectina-1 direcionada para rnai no tratamento do cÂncer - Google Patents
uso de uma abordagem baseada em galectina-1 direcionada para rnai no tratamento do cÂncerInfo
- Publication number
- BRPI0612334A2 BRPI0612334A2 BRPI0612334-1A BRPI0612334A BRPI0612334A2 BR PI0612334 A2 BRPI0612334 A2 BR PI0612334A2 BR PI0612334 A BRPI0612334 A BR PI0612334A BR PI0612334 A2 BRPI0612334 A2 BR PI0612334A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- hodgkin
- lymphoma
- melanoma
- head
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- 102000000795 Galectin 1 Human genes 0.000 title abstract 2
- 108010001498 Galectin 1 Proteins 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 208000032612 Glial tumor Diseases 0.000 abstract 4
- 206010018338 Glioma Diseases 0.000 abstract 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 4
- 201000010536 head and neck cancer Diseases 0.000 abstract 4
- 208000014829 head and neck neoplasm Diseases 0.000 abstract 4
- 208000030758 lung non-Hodgkin lymphoma Diseases 0.000 abstract 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 4
- 201000001441 melanoma Diseases 0.000 abstract 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 4
- 201000002528 pancreatic cancer Diseases 0.000 abstract 4
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 108091030071 RNAI Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000009368 gene silencing by RNA Effects 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000013508 migration Methods 0.000 abstract 1
- 230000005012 migration Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
USO DE UMA ABORDAGEM BASEADA EM GALECTINA-1 DIRECTONADA PARA RNAI NO TRATAMENTO DO CÂNCER. Mais particularmente refere-se a uma molécula de RNAi adequada para reduzir a expressão da galectina- 1, contendo qualquer uma das seqUências de IDENT. SEQ. Nº 1 a 33 e preferivelmente as seqUências de IDENT. SEQ. Nº 2, 3 ou 4, bem como seu uso como medicamento ou na produção de medicamento para tratar e retardar o avanço do câncer, preferivelmente o glioma, câncer pancreático, câncer de cabeça e pescoço, melanoma, câncer de pulmão de células não pequenas e linfomas não Hodgkin. A presente invenção também se refere a composições e métodos para tratar e retardar o avanço do câncer, preferivelmente glioma, câncer pancreático, câncer de cabeça e pescoço, melanoma, câncer de pulmão de células não pequenas e linfomas não Hodgkin, para reduzir a migração de células tumorais, preferivelmente células de glioma, câncer pancreático, câncer de cabeça e pescoço, melanoma, câncer de pulmão de células não pequenas e linfomas não Hodgkin e/ou aumentar a eficácia das terapias para tratamento do câncer, preferivelmente o glioma, câncer pancreático, câncer de cabeça e pescoço, melanoma, câncer de pulmão de células não pequenas e linfomas não Hodgkin, selecionados a partir do grupo que compreende quimioterapia, radioterapia, imunoterapia e/ou terapia gênica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67033405P | 2005-04-12 | 2005-04-12 | |
| PCT/EP2006/002170 WO2006108474A2 (en) | 2005-04-12 | 2006-03-09 | Use of a galectin-1-trageted rnai-based approach for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0612334A2 true BRPI0612334A2 (pt) | 2009-01-27 |
Family
ID=36933483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0612334-1A BRPI0612334A2 (pt) | 2005-04-12 | 2006-03-09 | uso de uma abordagem baseada em galectina-1 direcionada para rnai no tratamento do cÂncer |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7964575B2 (pt) |
| EP (1) | EP1874930B1 (pt) |
| JP (1) | JP5242377B2 (pt) |
| CN (1) | CN101228274A (pt) |
| AT (1) | ATE523591T1 (pt) |
| AU (1) | AU2006233522A1 (pt) |
| BR (1) | BRPI0612334A2 (pt) |
| CA (1) | CA2604288C (pt) |
| WO (1) | WO2006108474A2 (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8324367B2 (en) * | 2006-11-03 | 2012-12-04 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
| US9375440B2 (en) * | 2006-11-03 | 2016-06-28 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
| WO2009012384A2 (en) * | 2007-07-17 | 2009-01-22 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for the diagnosis, prognosis, and monitoring of immune disorders using galectin-1 |
| US9206427B2 (en) * | 2007-07-17 | 2015-12-08 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for the modulation of immune responses using galectin-1 |
| BRPI0919975A2 (pt) * | 2008-10-29 | 2015-12-15 | Bg Medicine Inc | imunoensaio para galectina-3 |
| CN101984056B (zh) * | 2009-07-10 | 2013-04-17 | 四川大学 | 人黑色素瘤细胞相关的长非编码rna的rna干扰靶点rna及用途 |
| CN101619312B (zh) * | 2009-07-10 | 2011-04-20 | 四川大学 | 人黑色素瘤细胞特异表达的长非编码rna序列及其用途 |
| CA3061784C (en) | 2009-11-13 | 2023-09-26 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1 |
| WO2014145749A1 (en) * | 2013-03-15 | 2014-09-18 | The Brigham And Women's Hospital, Inc. | Targeted polymeric inflammation-resolving nanoparticles |
| US20160215052A1 (en) * | 2013-07-24 | 2016-07-28 | Dana-Farber Cancer Institute, Inc. | Anti-galectin-1 (gal1) monoclonal antibodies and fragments thereof for neutralizing gal1 |
| US11576976B2 (en) * | 2015-01-21 | 2023-02-14 | D. R. NANO Co., Ltd. | Method of treating cancer by using siRNA nanocomplexes |
| EP3263135B1 (en) * | 2015-02-25 | 2020-01-15 | Bioneer Corporation | Pharmaceutical composition for treating cancer comprising microrna as active ingredient |
| GB201520600D0 (en) * | 2015-11-23 | 2016-01-06 | Univ Leuven Kath | Treatment of central nervous tumours |
| CN107540738B (zh) * | 2017-04-10 | 2020-04-24 | 清远职业技术学院 | 一种香港巨牡蛎半乳凝素ChGalectin及其制备方法和应用 |
| CA3102155A1 (en) | 2018-06-29 | 2020-01-02 | Glykos Biomedical Oy | Conjugates |
| US20230038373A1 (en) | 2019-12-18 | 2023-02-09 | Glykos Biomedical Oy | Stabile conjugate |
| US11649460B2 (en) * | 2020-03-20 | 2023-05-16 | Joao Francisco Peinado Pereira | DNA aptamers, method for inhibiting human galectin-1 and method of treating a mammal in need thereof |
| CN116785437B (zh) * | 2023-06-16 | 2026-03-24 | 中国医学科学院肿瘤医院 | KLF12或KLF12表达促进剂在制备用于抑制Galectin-1表达的药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1325116A2 (en) * | 2000-10-04 | 2003-07-09 | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. | Isoprenoid-dependent ras anchorage (idra) proteins |
| US20020173478A1 (en) * | 2000-11-14 | 2002-11-21 | The Trustees Of The University Of Pennsylvania | Post-transcriptional gene silencing by RNAi in mammalian cells |
| EP1386004A4 (en) * | 2001-04-05 | 2005-02-16 | Ribozyme Pharm Inc | MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID |
| WO2003070912A2 (en) * | 2001-06-06 | 2003-08-28 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| WO2002097114A2 (en) * | 2001-05-29 | 2002-12-05 | Sirna Therapeutics, Inc. | Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv |
| US7148342B2 (en) * | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
| AU2003255337A1 (en) * | 2002-07-31 | 2004-02-23 | Kylix B.V. | Use of genes identified to be involved in tumor development for the development of anti-cancer drugs |
| US20070178458A1 (en) * | 2003-09-05 | 2007-08-02 | O'brien Philippa | Methods of diagnosis and prognosis of ovarian cancer II |
-
2006
- 2006-03-09 EP EP06707489A patent/EP1874930B1/en not_active Expired - Lifetime
- 2006-03-09 US US11/911,342 patent/US7964575B2/en not_active Expired - Fee Related
- 2006-03-09 CA CA2604288A patent/CA2604288C/en not_active Expired - Lifetime
- 2006-03-09 JP JP2008505747A patent/JP5242377B2/ja not_active Expired - Fee Related
- 2006-03-09 BR BRPI0612334-1A patent/BRPI0612334A2/pt not_active Application Discontinuation
- 2006-03-09 CN CNA2006800163765A patent/CN101228274A/zh active Pending
- 2006-03-09 WO PCT/EP2006/002170 patent/WO2006108474A2/en not_active Ceased
- 2006-03-09 AT AT06707489T patent/ATE523591T1/de not_active IP Right Cessation
- 2006-03-09 AU AU2006233522A patent/AU2006233522A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2604288C (en) | 2021-07-06 |
| EP1874930A2 (en) | 2008-01-09 |
| US7964575B2 (en) | 2011-06-21 |
| CA2604288A1 (en) | 2006-10-19 |
| WO2006108474A3 (en) | 2006-12-21 |
| JP5242377B2 (ja) | 2013-07-24 |
| EP1874930B1 (en) | 2011-09-07 |
| US20100120891A1 (en) | 2010-05-13 |
| JP2008535504A (ja) | 2008-09-04 |
| AU2006233522A1 (en) | 2006-10-19 |
| WO2006108474A2 (en) | 2006-10-19 |
| CN101228274A (zh) | 2008-07-23 |
| ATE523591T1 (de) | 2011-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006108474A3 (en) | Use of a galectin-1-trageted rnai-based approach for the treatment of cancer | |
| MX2009006466A (es) | Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina. | |
| UA108193C2 (uk) | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| NO20062876L (no) | Sammensetninger til kombinert radio- og kjemoterapi, og fremgangsmater | |
| IL184617A0 (en) | Dr5 antibodies and uses thereof | |
| BRPI0510475B8 (pt) | adenovírus quimérico recombinante, uso do mesmo no tratamento de câncer e métodos de inibição de crescimento de uma célula de câncer, de fornecimento de uma proteína terapêutica a uma célula e para o isolamento do adenovírus | |
| TW200509967A (en) | Compositions and methods for WT1 specific immunotherapy | |
| BRPI0808940A8 (pt) | anticorpo humano ou fragmento de ligação do mesmo, antígeno, polinucleotídeo, vetor, célula hospedeira, método para preparar um anticorpo ou um fragmento de ligação ou cadeia(s) de imunoglobulina do mesmo, anticorpo, cadeia de imunoglobulina ou um fragmento de ligação do mesmo, composição, usos do anticorpo ou fragmento de ligação, de um antígeno, de um polinucleotídeo, de um vetor, ou de uma célula, e de uma molécula de ligação a antígeno tumoral, método para clonagem molecular de um anticorpo, e, kit para o diagnóstico de um tumor | |
| WO2002083171A3 (en) | Cancer treatment by using fap-alpha specific antibodies | |
| SG163583A1 (en) | Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment | |
| BR112015009559A2 (pt) | uso de composto antissenso na preparação de medicamento para tratamento de cãncer, composto antissenso e composição farmacêutica | |
| IL190796A0 (en) | Compositions and their uses for gene therapy of bone conditions | |
| WO2004076644A3 (en) | A composition for delivering an agent to a target cell and uses thereof | |
| EA201492148A1 (ru) | Способ лечения немелкоклеточного рака легких | |
| BRPI0508700A (pt) | uso de sns-595, composição farmacêutica, e, pó liofilizado | |
| MX360085B (es) | Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso. | |
| WO2021092464A3 (en) | Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy | |
| MX2009010269A (es) | Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana. | |
| PH12022553153A1 (en) | Binding molecules for the treatment of cancer | |
| ATE514718T1 (de) | Peptabody für krebsbehandlung | |
| GB0418388D0 (en) | Cell therapy | |
| WO2013066485A3 (en) | Compositions and methods for treatment of metastatic cancer | |
| BR112012022641A2 (pt) | peptídeos hjurp e vacinas que incluem os mesmos | |
| WO2023092153A3 (en) | Methods and compositions targeting nucleus accumbens-associated protein-1 for treatment of autoimmune disorders and cancers | |
| EP2513136A4 (en) | PEPTIDES TMEM22 AND VACCINES COMPRISING THEM |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |